Respivert's multikinase inhibitors, an evaluation of WO2014033446 to WO2014033449.
Expert Opin Ther Pat
; 24(12): 1397-407, 2014 Dec.
Article
en En
| MEDLINE
| ID: mdl-25407284
ABSTRACT
These four patent applications all claim that N-aryl-N'-pyrazol-5-yl urea derivatives , related to RV-568, which are inhibitors of p38, Syk and Src kinases. All four applications claim their use in the treatment of inflammatory diseases, notably asthma and chronic obstructive pulmonary disease. The four applications are primarily differentiated by the claimed substitution of the pyrazole ring. This is accompanied by differential kinase specificity profiles. Many of the exemplified compounds show reduced potency as p38 inhibitors but high potency as inhibitors of Syk and/or Src kinases.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Patentes como Asunto
/
Proteínas Quinasas p38 Activadas por Mitógenos
/
Inhibidores de Proteínas Quinasas
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Expert Opin Ther Pat
Asunto de la revista:
TERAPEUTICA
Año:
2014
Tipo del documento:
Article
País de afiliación:
Reino Unido